
Clinga 75mg Tablet
Marketer
Curis Lifecare
Salt Composition
Clopidogrel (75mg)
Overview Clinga 75mg Tablet
CardioGuard 75mg tablets are antiplatelet agents, preventing the formation of dangerous blood clots within your arteries and veins. This significantly reduces the likelihood of stroke or heart attack, making it a cornerstone of cardiovascular protection. CardioGuard 75mg is prescribed for individuals at elevated risk of heart disease, including those with peripheral arterial disease (circulatory issues stemming from narrowed blood vessels), recent stroke or myocardial infarction, arrhythmias, and post-stenting patients. It's also employed alongside other medications to manage acute myocardial infarction and unstable angina. This medication can be ingested with or without food, consistently at the same time daily. Continued use is crucial even in the absence of symptoms; discontinuation raises the risk of stroke or heart attack. The most prevalent side effect is increased bleeding, potentially manifesting as bruising, epistaxis, hematuria, melena (dark stools), or heavier menstrual flow. Wounds may take longer to heal. While typically mild and self-limiting, persistent or concerning bleeding necessitates immediate medical attention. CardioGuard is contraindicated in individuals with active internal bleeding, such as from a peptic ulcer or intracranial hemorrhage. Prior to initiating therapy, inform your physician of any history of bleeding disorders or recent major trauma or surgery. Temporary cessation may be necessary before elective surgical or dental procedures.
Uses of Clinga 75mg Tablet
Reducing the risk of cardiovascular events
Major Benefits of Clinga 75mg Tablet:
Administer this medication precisely as prescribed by your physician, adhering to both the dosage and treatment length. The tablet should be swallowed whole; avoid chewing, crushing, or fracturing it. Clinga 75mg Tablets can be ingested with or without food, however, consistent daily timing is recommended.
Common Side effects of Clinga 75mg Tablet:
- Abdominal pain
- Bruise
- Diarrhea
- Hematoma
- Nosebleeds
- Gastrointestinal bleeding
- Dyspepsia
How to use Clinga 75mg Tablet:
Administer this medication precisely as your physician directs, adhering to the prescribed dosage and treatment length. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Clinga 75mg Tablets can be consumed with or without food, though consistent timing is recommended.
How Clinga 75mg Tablet works:
Aggrenox 75mg tablets inhibit platelet aggregation, reducing the risk of dangerous thrombus formation and subsequently lowering the likelihood of myocardial infarction or cerebrovascular accident.
SAFETY ADVICE
AlcoholCAUTION
Use caution when drinking alcohol while taking Clinga 75mg tablets. Seek medical advice.
PregnancyCONSULT YOUR DOCTOR
The use of Clinga 75mg tablets during pregnancy may pose risks. While human research is scarce, animal studies indicate potential harm to the fetus. A physician will assess the advantages against possible dangers before recommending this medication. Seek medical advice.
Breast feedingSAFE IF PRESCRIBED
It is likely safe to breastfeed while taking Clinga 75mg tablets. Available human data indicates minimal infant risk associated with the medication.
DrivingSAFE
Driving ability is typically unaffected by Clinga 75mg Tablets.
KidneySAFE IF PRESCRIBED
Clinga 75mg tablets pose no safety concerns for patients with renal impairment; no dosage modification is necessary.
LiverSAFE IF PRESCRIBED
Clinga 75mg tablets may be administered to patients with hepatic impairment without modification of the prescribed dosage.
What if you forget to take Clinga 75mg Tablet :
Should you forget to take your Clinga 75mg Tablet, administer it immediately. If, however, your next scheduled dose is imminent, omit the missed dose and resume your usual dosing pattern. Avoid taking a double dose.
Facts to Know About Clinga 75mg Tablet
| Label | Value |
|---|---|
| Chemical Type | Amino acid alkyl esters |
| Developing Habits | No. |
| Type of Therapy | KINSHIP |
| Actions | ADP receptor antagonists (P2Y12 inhibitors) |
